Program
opemalirsen
Also written as “AZD2373 subcutaneous injection”, “AZD2373-Arm 1” and “AZD2373-Arm 2”.
Its studies are mostly in Renal Insufficiency, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 41 open or running | phase 2since Jan 24, 2025 | Feb 12, 2020 | Oct 4, 2027phase 2 · NCT06824987 |
- Named in AstraZeneca’s own pipeline as
opemalirsen
, phase 2, as of Oct 30, 2026 (source).
Also a collaborator on its studies: parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 12, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04269031 · 30 enrolled · United States
- Apr 1, 2022Phase 1 study in Healthy VolunteersNCT05351047 · 24 enrolled · United States
- Jan 24, 2025Phase 2 study in APOL1-Mediated Kidney DiseaseNCT06824987 · 63 enrolled · United States, United Kingdom
- Jul 28, 2025Phase 1 study in Renal InsufficiencyNCT07154901 · 35 enrolled · United States
Ahead
- Oct 4, 2027Primary completion: phase 2 study in APOL1-Mediated Kidney DiseaseNCT06824987
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07154901Renal Insufficiency · United States | 1 | Completed | Jun 15, 2026 | 35 |
| NCT06824987APOL1-Mediated Kidney Disease · United States, United Kingdom | 2 | Active, not recruiting | Oct 4, 2027 | 63 |
| NCT05351047Healthy Volunteers · United States | 1 | Completed | Jul 6, 2023 | 24 |
| NCT04269031Healthy Volunteers · United States | 1 | Completed | Aug 31, 2021 | 30 |
How it is read
Names in the registry
- “AZD2373 subcutaneous injection”, 2 entries
- “AZD2373-Arm 1”, 1 entry
- “AZD2373-Arm 2”, 1 entry
- “Opemalirsen (AZD2373)”, 1 entry
Conditions, from the studies’ own filings
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.